SoylentNews is people
SoylentNews
Two clinical trials for cancer were recently halted for the best possible reason; the drugs worked so well that it would be unethical to continue. One trial was for melanoma and the other was for lung cancer, but the drug-target was the same: Programmed cell death protein 1 (PD-1).
PD-1 is a protein that inhibits responses from T cells. Cancer often takes advantage of the PD-1 pathway to prevent a productive immune response that would otherwise kill the cancer. The drugs in both the clinical trials are antibodies that bind to PD-1, thus preventing cancer-mediated inhibition of the immune response. As this is a general mechanism that cancer uses to evade the immune system, it will likely be effective at treating other forms of cancer besides melanoma and lung cancer. Also, since the drugs are targeting T cells and not the cancer directly, resistance will not develop as easily.
http://pipeline.corante.com/archives/2015/04/17/stopped_for_efficacy_again.php
http://pipeline.corante.com/archives/2015/03/24/the_best_way_to_halt_a_clinical_trial.php
https://en.wikipedia.org/wiki/Programmed_cell_death_1
We looked around briefly and also found:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
http://www.reuters.com/article/2015/03/24/us-merck-melanoma-idUSKBN0MK1FO20150324
(Score: 5, Informative) by wonkey_monkey on Sunday April 19 2015, @08:14AM
If you can't back up your claim then we have to assume that you're full of shit and lying.
That's only if I can't back up my claim. If I simply don't, you're free to assume whatever you like.
Not every statement absolutely requires a citation. If you asked me what the weather was like here, and I said it was sunny, would you go round demanding proof?
My original "yes" response was just me being glib, based on the fact that, to me, the answer is, once stated, obvious enough to not really need a citation.
Still, if you must have one, there's one in one of the links in the summary from David Young MD:
The arm of the trial where the patients received the investigational drug did so well compared to the control arm (that received standard therapy) it was thought no longer ethical to withhold the investigational drug. As part of the trial design (and FDA regulations) the patients in the control arm were allowed to receive the investigational drug. The control arm patient were allowed to "cross over" to the investigational drug arm. In these situations, some of the patients in the control arm benefit from the investigational drug and it makes it very difficult to compare overall survival between the investigational arm and the control arm because some of the control arm patients ended up getting the investigational drug. In these settings it is the "progression free survival" that is much better in the investigational arm.
systemd is Roko's Basilisk
(Score: 2) by wonkey_monkey on Sunday April 19 2015, @03:27PM
If you can't back up your claim then we have to assume that you're full of shit and lying.
I just thought of a third option: I could just be mistaken.
systemd is Roko's Basilisk